MYRACLE THERAPEUTICS INC

Biotech · Private

Small-molecule HDAC11 inhibitors for metabolic disease and obesity treatment

Grants
$324K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Discovery and optimization of novel, selective HDAC11 inhibitors for the treatment of obesity and related diseases.$324,466
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2079STEMCELLLIFE LLC——
2080Synergyan, LLC——
2081Rhino Health Inc.—$7.0M
2082MYRACLE THERAPEUTICS INC——
2083Daedalus Systems Inc./de—$11M
2084Reclaim Pharmaceutical Waste Management, LLC——
2085Medium Corp—$31M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.